First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

  • days left to enroll
  • participants needed
  • sponsor
    EMD Serono Research & Development Institute, Inc.
Updated on 13 June 2022


The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), maximum tolerated dose (MTD) (if reached) and early signs of efficacy of M4076 monotherapy in participants with solid tumors in dose escalation (Part 1A). Once the recommended dose for expansion (RDE) is declared in Part 1A, a preliminary food effect cohort, Part 1B, will follow at the RDE determined from Part 1A.

Condition Advanced Solid Tumors
Treatment M4076
Clinical Study IdentifierNCT04882917
SponsorEMD Serono Research & Development Institute, Inc.
Last Modified on13 June 2022


Yes No Not Sure

Inclusion Criteria

Participants with advanced solid tumors, for whom no standard of care therapy exists or for whom is not considered sufficiently effective, or who cannot tolerate standard of care
Participants with Eastern Cooperative Oncology Group Performance status 0 or 1
Adequate hematological, hepatic, and renal function as defined in the protocol
Participants in Part 1B (the preliminary food effect assessment) must agree to provide paired tumor biopsies if not contraindicated for medical reasons
Other protocol defined inclusion criteria could apply

Exclusion Criteria

Clinically significant (i.e., active) uncontrolled intercurrent illness including, but not limited to
Active infection (i.e., requiring systemic antibiotics or antifungals)
Uncontrolled arterial hypertension
Severe cardiac arrhythmia requiring medication
Cerebral vascular accident/stroke
Has known ataxia telangiectasia
Participants with tumors harboring previously identified ATM mutations
Participants with hypersensitivity to the active substance or to any of the excipients of M4076
Other protocol defined exclusion criteria could apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note